Antibiotic options for treating community-acquired MRSA.

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is an increasing public health concern.
• Rising antibiotic resistance is diminishing effective oral treatment options for CA-MRSA infections.
• Geographical variations in susceptibility impact empiric treatment choices.

Purpose of the Study:

• To review current pharmacotherapeutic options for CA-MRSA infections.
• To highlight challenges in empiric oral therapy selection.
• To emphasize the need for comparative clinical trials.

Main Methods:

• Literature review of current CA-MRSA treatment guidelines and resistance patterns.
• Analysis of available oral and intravenous antibiotic options.
• Discussion of factors influencing treatment decisions, including adverse effects and infection severity.

Main Results:

• Fluoroquinolones and clindamycin are often unsuitable for empiric CA-MRSA treatment.
• Trimethoprim-sulfamethoxazole, doxycycline, and linezolid are viable oral options, with selection dependent on patient factors.
• Intravenous treatment options show low resistance, with choice guided by infection site and severity.

Conclusions:

• Empiric oral therapy for CA-MRSA infections requires careful consideration of resistance and patient-specific factors.
• Further clinical trials comparing antibiotic efficacy in both outpatient and inpatient settings are crucial.
• Development of enhanced empiric therapy algorithms is needed to guide clinical practice.